Cargando…
Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries
INTRODUCTION: The aim of this study was to investigate the attitudes towards use of androgen deprivation therapy (ADT) as monotherapy for localized or locally advanced prostate cancer (PC). MATERIAL AND METHODS: A survey using a 28-item, structured, quantitative questionnaire about the management of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Polish Urological Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318023/ https://www.ncbi.nlm.nih.gov/pubmed/34336233 http://dx.doi.org/10.5173/ceju.2021.0343.R1 |
_version_ | 1783730169566986240 |
---|---|
author | Mitropoulos, Dionysios Chlosta, Piotr Häggman, Michael Ström, Torbjorn Markussis, Vyron |
author_facet | Mitropoulos, Dionysios Chlosta, Piotr Häggman, Michael Ström, Torbjorn Markussis, Vyron |
author_sort | Mitropoulos, Dionysios |
collection | PubMed |
description | INTRODUCTION: The aim of this study was to investigate the attitudes towards use of androgen deprivation therapy (ADT) as monotherapy for localized or locally advanced prostate cancer (PC). MATERIAL AND METHODS: A survey using a 28-item, structured, quantitative questionnaire about the management of patients with PC was conducted in eight European countries between February and May 2018. Survey recipients were selected from a private database of healthcare providers. RESULTS: Overall, 375 physicians completed the survey (response rate, 58%). Participants were urologists (71.2%) or medical oncologists (28.8%), with a mean practice duration of 19.9 years and with university hospital or cancer center (41.6%), non-teaching hospital (38.4%) or private-sector clinic (20.0%) affiliations. Median proportions of physicians considering ADT as monotherapy to treat patients with PC in different risk groups varied between countries, but overall were: high/very high-risk, 60%; intermediate-risk, 30%; low-risk, 7.5%. The use of ADT monotherapy in the different risk groups also varied by medical specialty and type of affiliation. Proportions of participants applying different target thresholds for testosterone (T) levels also varied by country, but overall were: <50 ng/dL, 29.9%; <32 ng/dL, 4.8%; <20 ng/dL, 54.3%; castration but no specific target, 11%. More than half of participants (58.7%) determined target T levels only when prostate-specific antigen level was increased. CONCLUSIONS: Our multinational survey provides evidence that PC management varies across European countries and with clinical context, and frequently diverges from European Association of Urology (EAU) – European Society for Radiotherapy and Oncology (ESTRO) – European Society of Urogenital Radiology (ESUR) – International Society of Geriatric Oncology (SIOG) guidelines. Strategies for effective implementation of evidence-based recommendations in clinical practice may be needed to optimize patient outcomes. |
format | Online Article Text |
id | pubmed-8318023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Polish Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-83180232021-07-30 Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries Mitropoulos, Dionysios Chlosta, Piotr Häggman, Michael Ström, Torbjorn Markussis, Vyron Cent European J Urol Original Paper INTRODUCTION: The aim of this study was to investigate the attitudes towards use of androgen deprivation therapy (ADT) as monotherapy for localized or locally advanced prostate cancer (PC). MATERIAL AND METHODS: A survey using a 28-item, structured, quantitative questionnaire about the management of patients with PC was conducted in eight European countries between February and May 2018. Survey recipients were selected from a private database of healthcare providers. RESULTS: Overall, 375 physicians completed the survey (response rate, 58%). Participants were urologists (71.2%) or medical oncologists (28.8%), with a mean practice duration of 19.9 years and with university hospital or cancer center (41.6%), non-teaching hospital (38.4%) or private-sector clinic (20.0%) affiliations. Median proportions of physicians considering ADT as monotherapy to treat patients with PC in different risk groups varied between countries, but overall were: high/very high-risk, 60%; intermediate-risk, 30%; low-risk, 7.5%. The use of ADT monotherapy in the different risk groups also varied by medical specialty and type of affiliation. Proportions of participants applying different target thresholds for testosterone (T) levels also varied by country, but overall were: <50 ng/dL, 29.9%; <32 ng/dL, 4.8%; <20 ng/dL, 54.3%; castration but no specific target, 11%. More than half of participants (58.7%) determined target T levels only when prostate-specific antigen level was increased. CONCLUSIONS: Our multinational survey provides evidence that PC management varies across European countries and with clinical context, and frequently diverges from European Association of Urology (EAU) – European Society for Radiotherapy and Oncology (ESTRO) – European Society of Urogenital Radiology (ESUR) – International Society of Geriatric Oncology (SIOG) guidelines. Strategies for effective implementation of evidence-based recommendations in clinical practice may be needed to optimize patient outcomes. Polish Urological Association 2021-03-26 2021 /pmc/articles/PMC8318023/ /pubmed/34336233 http://dx.doi.org/10.5173/ceju.2021.0343.R1 Text en Copyright by Polish Urological Association https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Mitropoulos, Dionysios Chlosta, Piotr Häggman, Michael Ström, Torbjorn Markussis, Vyron Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries |
title | Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries |
title_full | Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries |
title_fullStr | Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries |
title_full_unstemmed | Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries |
title_short | Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries |
title_sort | androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight european countries |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318023/ https://www.ncbi.nlm.nih.gov/pubmed/34336233 http://dx.doi.org/10.5173/ceju.2021.0343.R1 |
work_keys_str_mv | AT mitropoulosdionysios androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries AT chlostapiotr androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries AT haggmanmichael androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries AT stromtorbjorn androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries AT markussisvyron androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries |